SRC and cancer: Dasatinib is a tyrosine kinase inhibitor that targets multiple kinases at nanomolar concentrations, including BCR-ABL, the Src family of kinases (Src, LCK, YES, FYN), c-KIT, EPHA2, and PDGFRβ1 in cancer cells [98,99].